A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort

Clinical Cancer Research

Volumn 22, Issue 18, 2016, Pages 4664-4675

  Terry, Kathryn L ^a,b   Schock, Helena ^c   Fortner, Renée T ^c   Hüsing, Anika ^a,b   Fichorova, Raina N ^a,b   Yamamoto, Hidemi S ^a,b   Vitonis, Allison F ^a   Johnson, Theron ^c   Overvad, Kim ^d   Tjønneland, Anne ^e   Boutron Ruault, Marie Christine ^f,g   Mesrine, Sylvie ^f,g   Severi, Gianluca ^f,g,h,i   Dossus, Laure ^j   Rinaldi, Sabina ^j   Boeing, Heiner ^k   Benetou, Vassiliki ^l,m   Lagiou, Pagona ^l,m   Trichopoulou, Antonia ^l,m   Krogh, Vittorio ⁿ   Kuhn, Elisabetta ^o   Panico, Salvatore ^p   Bueno De Mesquita, H Bas ^q   Onland Moret, N Charlotte ^r   Peeters, Petra H ^r   Gram, Inger Torhild ^s   Weiderpass, Elisabete ^s,t,u,v   Duell, Eric J ^w   Sanchez, Maria Jose ^x,y   Ardanaz, Eva ^y,z,aa   Etxezarreta, Nerea ^y,ab   Navarro, Carmen ^y,ac,ad   Idahl, Annika ^ae   Lundin, Eva ^ae   Jirström, Karin ^af,ag   Manjer, Jonas ^af,ag   Wareham, Nicholas J ^ah   Khaw, Kay Tee ^ai   Byrne, Karl Smith ^aj   Travis, Ruth C ^aj   Gunter, Marc J ^ak   Merritt, Melissa A ^ak   Riboli, Elio ^ak   Cramer, Daniel W ^a   Kaaks, Rudolf ^b   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d AARHUS UNIVERSITY   (Denmark)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h Human Genetics Foundation (HuGeF)   (Italy)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^k GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^l Helenic Health Foundation   (Greece)

^m UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o UNIVERSITY OF FERRARA   (Italy)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^q NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^r UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^s UNIVERSITY OF TROMSØ   (Norway)

^t CANCER REGISTRY OF NORWAY   (Norway)

^u KAROLINSKA INSTITUTE   (Sweden)

^v FOLKHÄLSAN RESEARCH CENTER   (Finland)

^w CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^x ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^y CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^z INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^aa Recinto de Complejo Hospitalario de Navarra   (Spain)

^ab Basque Government   (Spain)

^ac DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^ad UNIVERSITY OF MURCIA   (Spain)

^ae UMEÅ UNIVERSITY   (Sweden)

^af LUND UNIVERSITY   (Sweden)

^ag LUND UNIVERSITY HOSPITAL   (Sweden)

^ah MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^ai UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^aj UNIVERSITY OF OXFORD   (United Kingdom)

^ak IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72-4 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY CANCER DIAGNOSIS; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; CANCER GRADING; COHORT ANALYSIS; EUROPE; INCIDENCE; MIDDLE AGED; OVARY TUMOR; PROCEDURES; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DETECTION OF CANCER; EUROPE; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE;

EID: 84990062718     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0316     Document Type: Article

References (34)

1. American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2015.
2. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004;20:53-70.
3. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
4. U.S. Food and Drug Administration. 510(K) Substantial equivalence determination decision summary. Available from: http://www.accessdata. fda.gov/cdrh≥docs/reviews/K081754.pdf.
5. U.S. Food and Drug Administration. HE4 EIA. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/220028-4403b1-02-Proposed% 20HE4%20EIA%20Package%20Insert%20%20.pdf.
6. U.S. Food and Drug Administration. 510 (k) Substantial equivalence determination decision summary. Available from: http://www.accessdata. fda.gov/cdrh≥docs/reviews/K042731.pdf.
7. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancermortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303.
8. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortalityin the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945-56.
9. KobayashiH, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18:414-20.
10. Anderson GL,McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested casecontrol study. J Natl Cancer Inst 2010;102:26-38.
11. Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, et al. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecol Oncol 2015;139:253-60.
12. Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, et al. Potential role ofHE4in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 2011;103:1630-4.
13. Bingham S, Riboli E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004;4:206-15.
14. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
15. Hainaut P, Vozar B, Rinaldi S, Riboli E, Caboux E. The European Prospective Investigation into Cancer and Nutrition biobank. Methods Mol Biol 2011;675:179-91.
16. Li K, Husing A, Fortner RT, Tjønneland A, Hansen L, Dossus L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. Br J Cancer 2015;112:1257-65.
17. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
18. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011; 4:365-74.
19. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 2011; 4:375-83.
20. Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol 2013;31:387-92.
21. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 2013;119:3454-61.
22. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015;33:2062-71.
23. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21: 206s-10s.
24. Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Arch Gynecol Obstet 2013;288:167-72.
25. Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB, et al. HE4 combined with CA125: favorable screening tool for ovarian cancer. Med Oncol 2014;31:808.
26. Karlsen MA, Hogdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer-An international multicenter study in women with an ovarian mass. Gynecol Oncol 2015;138:640-6.
27. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012;127:379-83.
28. Kristjansdottir B, Levan K, Partheen K, Sundfeldt K. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol 2013;131:52-8.
29. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108: 402-8.
30. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104:863-70.
31. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T,Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66.
32. Jacobs I, Menon U. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res 2011;4:299-302.
33. Pepe MS, Li CI, Feng Z. Improving the quality of biomarker discovery research: the right samples and enough of them. Cancer Epidemiol Biomarkers Prev 2015;24:944-50.
34. Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, et al. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst 2015;107:djv012.